TY - JOUR A1 - Schiele, Miriam A. A1 - Ziegler, Christiane A1 - Kollert, Leonie A1 - Katzorke, Andrea A1 - Schartner, Christoph A1 - Busch, Yasmin A1 - Gromer, Daniel A1 - Reif, Andreas A1 - Pauli, Paul A1 - Deckert, Jürgen A1 - Herrmann, Martin J. A1 - Domschke, Katharina T1 - Plasticity of Functional MAOA Gene Methylation in Acrophobia JF - International Journal of Neuropsychopharmacology N2 - Epigenetic mechanisms have been proposed to mediate fear extinction in animal models. Here, MAOA methylation was analyzed via direct sequencing of sodium bisulfite-treated DNA extracted from blood cells before and after a 2-week exposure therapy in a sample of n = 28 female patients with acrophobia as well as in n = 28 matched healthy female controls. Clinical response was measured using the Acrophobia Questionnaire and the Attitude Towards Heights Questionnaire. The functional relevance of altered MAOA methylation was investigated by luciferase-based reporter gene assays. MAOA methylation was found to be significantly decreased in patients with acrophobia compared with healthy controls. Furthermore, MAOA methylation levels were shown to significantly increase after treatment and correlate with treatment response as reflected by decreasing Acrophobia Questionnaire/Attitude Towards Heights Questionnaire scores. Functional analyses revealed decreased reporter gene activity in presence of methylated compared with unmethylated pCpGfree_MAOA reporter gene vector constructs. The present proof-of-concept psychotherapy-epigenetic study for the first time suggests functional MAOA methylation changes as a potential epigenetic correlate of treatment response in acrophobia and fosters further investigation into the notion of epigenetic mechanisms underlying fear extinction. KW - monoamine oxidase A KW - anxiety KW - extinction KW - epigenetics KW - DNA methylation Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-228571 VL - 21 IS - 9 ER - TY - THES A1 - Kollert, Leonie T1 - Epigenetics of anxiety and depression – a differential role of TGFB-Inducible Early Growth Response Protein 2 gene promoter methylation T1 - Epigenetik von Angst und Depression – Die differentielle Rolle von TGFB-Inducible Early Growth Response Protein 2 Gen Promotor Methylierung N2 - Among mental disorders, panic disorder (PD) is one of the most common anxiety disorders characterized by recurring and unexpected episodes of extreme fear i.e. panic attacks. PD displays lifetime prevalence rates in the general population between 2.1-4.7 % and in about 30 to 40 % occurs comorbid with major depressive disorder (MDD). Differential methylation levels of the monoamine oxidase A (MAOA) gene have previously been associated with the etiology of both PD and MDD. The TGFB-Inducible Early Growth Response Protein 2 (TIEG2; alias KLF11), an activating transcription factor of the MAOA gene, has been reported to be increased in MDD, but has not yet been investigated in PD on any level. Therefore, in an attempt to further define the role of an impaired TIEG2-MAOA pathway in anxiety and affective disorders, in the present thesis TIEG2 promoter DNA methylation was analyzed in two independent samples of I) PD patients with or without comorbid MDD in a case/control design and II) MDD patients with and without anxious depression. Additionally, in PD patients of sample I), TIEG2 methylation was correlated with Beck Depression Inventory (BDI-II) scores. Finally, in a third independent healthy control sample, correlation of TIEG2 promoter methylation levels with Anxiety Sensitivity Index (ASI) scores as a PD-related measure was analyzed. No overall association of TIEG2 promoter methylation with PD was detected. However, PD patients with comorbid MDD showed significant TIEG2 hypomethylation compared to PD patients without comorbid MDD (p=.008) as well as to healthy controls (p=.010). In addition, MDD patients without anxious features displayed a statistical trend in decreased TIEG2 methylation in comparison to MDD patients with anxious depression (p=.052). Furthermore, TIEG2 methylation was negatively correlated with BDI-II scores in PD patients (p=.013) and positively correlated with ASI scores in the healthy control sample (p=.043). In sum, the current study suggests TIEG2 promoter hypomethylation as a potential epigenetic marker of MDD comorbidity in PD or of non-anxious depression, respectively. If replicated and verified in future studies, altered TIEG2 methylation might therefore represent a differential pathomechanism of anxiety and mood disorders. N2 - Die Panikstörung (PD) ist eine der häufigsten Angststörungen, die durch wiederkehrende und unerwartete Episoden extremer Angst gekennzeichnet ist. Die PD tritt in der Allgemeinbevölkerung mit Lebenszeitprävalenzraten zwischen 2,1 und 4,7 % und in etwa 30 bis 40 % der Fälle komorbid mit einer schweren Depression (MDD) auf. Unterschiedliche Methylierungs-Niveaus des Monoaminoxidase A (MAOA) Gens wurden bereits mit der Ätiologie von PD und MDD assoziiert. Das TGFB-Inducible Early Growth Response Protein 2 (TIEG2; alias KLF11) fungiert als ein aktivierender Transkriptionsfaktor des MAOA Gens und wurde bei Patienten mit MDD in seiner Expression erhöht gefunden. Bei der PD wurde TIEG2 bis heute jedoch noch nicht untersucht. Um die Rolle eines gestörten TIEG2-MAOA Signalwegs bei Angst- und affektiven Störungen genauer zu definieren, wurde in der vorliegenden Studie die Methylierung des TIEG2 Promotors in zwei unabhängigen Stichproben bestehend aus I) PD Patienten mit bzw. ohne komorbider MDD, sowie II) MDD Patienten mit bzw. ohne erhöhte Angstsymptomen untersucht. Zusätzlich wurde in der PD Stichprobe die TIEG2 Methylierung mit dem Beck Depression Inventar II (BDI-II) korreliert. Schließlich wurde in einer dritten unabhängigen Stichprobe gesunder Probanden die Korrelation der TIEG2 Methylierung mit den Punktwerten des Angstsensitivitätsindex (ASI) analysiert. Es wurde keine Assoziation von TIEG2 Promotor-Methylierung mit PD beobachtet. Allerdings waren PD Patienten mit komorbider MDD im Vergleich zu PD Patienten ohne komorbide MDD (p=,008) sowie zu gesunden Kontrollprobanden (p=,010) signifikant niedriger methyliert. MDD Patienten ohne ängstliche Symptome zeigten einen statistischen Trend von verringerte TIEG2 Methylierung im Vergleich zu MDD Patienten mit ängstlicher Depression (p=,052). Zusätzlich korrelierte die TIEG2 Methylierung negativ mit den BDI-II Werten bei PD Patienten (p=,013) und positiv mit den ASI Werten in der gesunden Probandenstichprobe (p=,043). KW - Epigenetik KW - Epigenetic Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-211268 ER -